Intraoperative BleedingNCT07585201
Dexmedetomidine Versus Nitroglycerin on Surgical Field Quality and Drug Cost in Functional Endoscopic Sinus Surgeries
A study of Intraoperative Bleeding and Functional Endoscopic Sinus Surgeries, run by Zagazig University at 1 site in Egypt.
Trial summary
Sinus surgery is one of the most prevalent ear, nose, and throat (ENT) surgeries, which is mainly carried out nowadays through functional endoscopic sinus surgery (FESS) and leads to significant improvement in the clinical symptoms of patients with rhinosinusitis. Read more about this study
- Who is it for?
- Ages 21 to 60 years
- Conditions the study is for
- Intraoperative Bleeding, Functional Endoscopic Sinus Surgeries, Hypotension
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2022to 1 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Physical status: American Society of Anesthesiologists (ASA) I \& II.
- Body Mass Index (BMI): 18.5-30 kg/m2.
- Type of operation: elective bilateral FESS.
- Type of anesthesia: general anesthesia.
Who cannot join
- Patients with known history of allergy to study drugs.
- Anticipated difficult intubation.
- Advanced hepatic, renal or cardiovascular diseases.
- Central nervous system disorder, metabolic disease, and electrolyte imbalance.
- Coagulopathies or taking drugs affecting coagulation.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of Dexmedetomidine Versus Nitroglycerin on Surgical Field Quality and Drug Cost in Functional Endoscopic Sinus Surgeries
Sinus surgery is one of the most prevalent ear, nose, and throat (ENT) surgeries, which is mainly carried out nowadays through functional endoscopic sinus surgery (FESS) and leads to significant improvement in the clinical symptoms of patients with rhinosinusitis. It is necessary to maintain safe conditions for this surgery, and the major problem reported during FESS under general anesthesia (GA) is impaired visibility due to excessive amount of bleeding. This is particularly important for the successful surgery of the ethmoid and sphenoid sinuses because even minimum amount of bleeding might seriously impair the successful completion of the surgery, increase the operational risk, and increase surgery time which are major concerns for both anesthesiologist and ENT specialist.
Controlled hypotension is the commonly used technique to limit blood loss and improve visualization in the surgical field during FESS, various techniques have been adopted to achieve controlled hypotension, one of them is the use of pharmacological drugs in the form of volatile anesthetics, direct-acting vasodilators, autonomic ganglion-blockers, and α-adrenergic receptor blockers.
Read more
Alpha-2 (α-2) receptors are found in the peripheral and central nervous systems, platelets and many other organs including the liver, pancreas, kidney, and eye. Stimulation of the receptors in the brain and spinal cord inhibits neuronal firing causing hypotension, bradycardia, sedation, and analgesia. Alpha-2 (α-2) agonist drugs have sympatholytic, sedative, anesthetic, and analgesic sparing effects, as well as vasoconstrictive effects and thereby reduce intraoperative bleeding. Also, the use of α-2 agonists in the perioperative period has been associated with reduced anesthetic requirements, decreased heart rate and blood pressure.
Dexmedetomidine is a highly selective α-2 adrenergic receptor agonist (selectivity ratio for α2: α1 is 1600:1). The sympatholytic effect of dexmedetomidine made it attractive to be used as a hypotensive drug during surgery because of decreasing heart rate (HR) and cardiac output (CO) without decreasing stroke volume unless the plasma concentrates reaches above 5.1 μg/mL. The cardiovascular effects of dexmedetomidine begin with initial hypertension following the administration of a loading dose, due to the activation of α 2B receptors located on vascular smooth muscle, with subsequent hypotension and bradycardia due to centrally mediated decrease in sympathetic tone. Dexmedetomidine also has sedative, amnesic, anxiolytic, hypnotic, and analgesic effects with minimal changes in respiratory variables. Furthermore, it reduces postoperative nausea, vomiting, and shivering. It also reduces delirium in patients after cardiac surgery.
Nitroglycerin is a directly acting vasodilator drug frequently used to produce controlled hypotension because it is easily titratable and having very rapid onset as well as rapid offset of action. However, the disadvantages of nitroglycerin are reflex tachycardia and venous congestion which leads to increased blood loss.
Aim of the work was improving surgical field quality and drug cost in patients undergoing Functional Endoscopic Sinus Surgeries by comparing between dexmedetomidine and nitroglycerin.
Read the detailed description
This study had been carried out in Anesthesia, Intensive Care and Pain management Department - Faculty of Medicine - Zagazig University Hospitals.
Sample size:
Assuming the average category scale was 73.33% vs 36.67% in group D vs group N, so the sample was 66 adult male and female undergoing FESS , 33 cases in each group (dexmedetomidine and nitroglycerin) using open EPI info with CI 95%, Power of test 80%.
Withdrawal criteria:
The patient has the right to withdraw from the study at any time without any negative consequences or harm on his/her medical treatment plan.
Randomization:
All Patients were randomly allocated into 2 equal groups. Patients were randomized using computer generated randomization table in a 1:1 ratio and allocated either in dexmedetomidine group (group D) or nitroglycerin group (group N).
Randomization assignments were kept in sealed envelopes until the day of surgery, and then they opened by the research anesthesiologist immediately prior to the operation.
Process:
- All participating patients were interviewed preoperatively during their preoperative preparation. The goal and endpoints of the study were discussed. Understanding of the technique was reviewed and emphasized.
- History was taken, clinical examination was done, and informed written consent was obtained.
- Fasting before the operation (8 hours for solid meal and 2 hours for clear fluids).
- IV line was inserted; midazolam (0.02-0.05 mg/kg) was given as a premedication, started IV fluids as ringer lactate (8-10 ml/kg).
- 10 minutes before induction of anesthesia, full monitoring including noninvasive arterial blood pressure, electrocardiogram, pulse oximetry, and capnogram (after induction of anesthesia) were applied and basal readings were recorded.
- Preoxygenation with 100% oxygen for 3 minutes before induction.
Group (D):
Started infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia.
Induction:
- Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg).
Maintenance:
- Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes.
- IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h. Group (N)
Induction:
- Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg).
Maintenance:
- Maintenance of anesthesia was done with isoflurane inhalation at 1-2 (MAC) and incremental doses of rocuronium 0.5 mg/kg every 45 minutes.
- IV infusion of nitroglycerin at a dose of 0.5-2 µg/kg/min. Both drugs (dexmedetomidine and nitroglycerin) were titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.
Operations for both groups were carried out by the same surgical team. All the patients, surgeons, and the attending anesthetist who was assigned to record the patients' parameters were blinded to the infused drugs. The randomization envelopes, the syringe pumps, and their code labels were prepared by an anesthetist independent in the study.
Recovery period:
Patients were recovered with neostigmine (0.05-0.08 mg/kg) and atropine, the standard analgesia (paracetamol) was started at a dose of (15 mg/kg) then patients were transferred to the post anesthesia care unit (PACU) for observation.
Measurements:
- The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system:-
Fromme and Boezaart scoring system:
Grade Assessment 0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible Heart rate and MAP basal readings were recorded then at 15 minutes time interval intraoperative.
Emergence time defined as the interval between discontinuation of the anesthetics to response of eye opening to the verbal command.
Recovery time defined as the time from end of surgery (i.e., final wound covered) until the patient left for the hospital ward were recorded.
The postoperative sedation was assessed with Ramsay Sedation Score Observation for any side effects or complications such as nausea, vomiting, shivering, dry mouth, bradycardia, tachycardia, and hypotension.
The cost of both drugs was recorded.
Data collection:
- Patient characteristics: age, sex, BMI, and physical status of patients included in the study.
- MAP, heart rate and assessment score of surgical field intraoperative.
- Emergence and recovery time.
- Sedation score.
- Drug cost.
- Side effects or complications.
- Being tested
- controlled hypotension using dexmedetomidine, controlled hypotension hypotension using nitroglycerin
- Keywords
- Dexamedomidine, Nitroglycerin, Controlled Hypotension, Functional Endoscopic Sinus Surgeries
- Medical subject headings
- Blood Loss, Surgical, Hypotension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
controlled hypotension using dexmedetomidineDrug
Started infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia.
Induction:
Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg).
Maintenance:
Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h.
Dexmedetomidine was titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.
controlled hypotension hypotension using nitroglycerinDrug
Induction:
- Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg).
Maintenance:
- Maintenance of anesthesia was done with isoflurane inhalation at 1-2 (MAC) and incremental doses of rocuronium 0.5 mg/kg every 45 minutes.
- IV infusion of nitroglycerin at a dose of 0.5-2 µg/kg/min. Nitorglycerin) was titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.
| Study group | Role | What they receive |
|---|---|---|
| Group D | Active comparator | dexmedetomidine as controlled hypotensive drug Receives: Drug: controlled hypotension using dexmedetomidine |
| Group N | Active comparator | Nitroglycerin as controlled hypotensive drug Receives: Drug: controlled hypotension hypotension using nitroglycerin |
What is being measured
The primary outcome is the main question the study is designed to answer.
The quality of the surgical field
The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system:
0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible
Measured: perioperative
Drug cost
estimate and compare the drug cost in both groups by Egyptian pounds
Measured: perioperative
Secondary outcomes (5)
Emergence time
the interval between discontinuation of the anesthetics to response of eye opening to the verbal command
Measured: perioperative
Mean arterial pressure
MAP basal readings were recorded then at 15 minutes time interval intraoperative till the end of the operation
Measured: basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes
Heart rate
Heart rate basal readings were recorded then at 15 minutes time interval intraoperative till the end of the operation
Measured: basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes , 120 minutes
Recovery time
the time from end of surgery (i.e., final wound covered) until the patient left for the hospital ward
Measured: perioperative
Complications
Observation for any side effects or complications such as nausea, vomiting, shivering, dry mouth, bradycardia, tachycardia, and hypotension.
Measured: perioperative
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2026
- Study start1 Sep 2022
- Primary completion28 Feb 2023
- Study completion1 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intraoperative BleedingStudies of the same condition, open and under way.
- More trials run by Zagazig UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zagazig University
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07585201
- Sponsor's protocol ID
- ZU-IRB #9667
- Status last verified
- Apr 2026
- First submitted
- 22 Apr 2026
- Last updated
- 13 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Dexmedetomidine Versus Nitroglycerin on Surgical Field Quality and Drug Cost in Functional Endoscopic Sinus Surgeries
- ClinicalTrials.gov ID
- NCT07585201
- Acronym / sponsor ID
- ZU-IRB #9667
- Keywords
- Dexamedomidine, Nitroglycerin, Controlled Hypotension, Functional Endoscopic Sinus Surgeries
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Zagazig UniversityOther government
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 28 Feb 2023 (actual)
- Study completion
- 1 Mar 2023 (actual)
- First posted
- 13 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sinus surgery is one of the most prevalent ear, nose, and throat (ENT) surgeries, which is mainly carried out nowadays through functional endoscopic sinus surgery (FESS) and leads to significant improvement in the clinical symptoms of patients with rhinosinusitis. It is necessary to maintain safe conditions for this surgery, and the major problem reported during FESS under general anesthesia (GA) is impaired visibility due to excessive amount of bleeding. This is particularly important for the successful surgery of the ethmoid and sphenoid sinuses because even minimum amount of bleeding might seriously impair the successful completion of the surgery, increase the operational risk, and increase surgery time which are major concerns for both anesthesiologist and ENT specialist.
Controlled hypotension is the commonly used technique to limit blood loss and improve visualization in the surgical field during FESS, various techniques have been adopted to achieve controlled hypotension, one of them is the use of pharmacological drugs in the form of volatile anesthetics, direct-acting vasodilators, autonomic ganglion-blockers, and α-adrenergic receptor blockers.
Alpha-2 (α-2) receptors are found in the peripheral and central nervous systems, platelets and many other organs including the liver, pancreas, kidney, and eye. Stimulation of the receptors in the brain and spinal cord inhibits neuronal firing causing hypotension, bradycardia, sedation, and analgesia. Alpha-2 (α-2) agonist drugs have sympatholytic, sedative, anesthetic, and analgesic sparing effects, as well as vasoconstrictive effects and thereby reduce intraoperative bleeding. Also, the use of α-2 agonists in the perioperative period has been associated with reduced anesthetic requirements, decreased heart rate and blood pressure.
Dexmedetomidine is a highly selective α-2 adrenergic receptor agonist (selectivity ratio for α2: α1 is 1600:1). The sympatholytic effect of dexmedetomidine made it attractive to be used as a hypotensive drug during surgery because of decreasing heart rate (HR) and cardiac output (CO) without decreasing stroke volume unless the plasma concentrates reaches above 5.1 μg/mL. The cardiovascular effects of dexmedetomidine begin with initial hypertension following the administration of a loading dose, due to the activation of α 2B receptors located on vascular smooth muscle, with subsequent hypotension and bradycardia due to centrally mediated decrease in sympathetic tone. Dexmedetomidine also has sedative, amnesic, anxiolytic, hypnotic, and analgesic effects with minimal changes in respiratory variables. Furthermore, it reduces postoperative nausea, vomiting, and shivering. It also reduces delirium in patients after cardiac surgery.
Nitroglycerin is a directly acting vasodilator drug frequently used to produce controlled hypotension because it is easily titratable and having very rapid onset as well as rapid offset of action. However, the disadvantages of nitroglycerin are reflex tachycardia and venous congestion which leads to increased blood loss.
Aim of the work was improving surgical field quality and drug cost in patients undergoing Functional Endoscopic Sinus Surgeries by comparing between dexmedetomidine and nitroglycerin.
Detailed description
This study had been carried out in Anesthesia, Intensive Care and Pain management Department - Faculty of Medicine - Zagazig University Hospitals.
Sample size:
Assuming the average category scale was 73.33% vs 36.67% in group D vs group N, so the sample was 66 adult male and female undergoing FESS , 33 cases in each group (dexmedetomidine and nitroglycerin) using open EPI info with CI 95%, Power of test 80%.
Withdrawal criteria:
The patient has the right to withdraw from the study at any time without any negative consequences or harm on his/her medical treatment plan.
Randomization:
All Patients were randomly allocated into 2 equal groups. Patients were randomized using computer generated randomization table in a 1:1 ratio and allocated either in dexmedetomidine group (group D) or nitroglycerin group (group N).
Randomization assignments were kept in sealed envelopes until the day of surgery, and then they opened by the research anesthesiologist immediately prior to the operation.
Process:
- All participating patients were interviewed preoperatively during their preoperative preparation. The goal and endpoints of the study were discussed. Understanding of the technique was reviewed and emphasized.
- History was taken, clinical examination was done, and informed written consent was obtained.
- Fasting before the operation (8 hours for solid meal and 2 hours for clear fluids).
- IV line was inserted; midazolam (0.02-0.05 mg/kg) was given as a premedication, started IV fluids as ringer lactate (8-10 ml/kg).
- 10 minutes before induction of anesthesia, full monitoring including noninvasive arterial blood pressure, electrocardiogram, pulse oximetry, and capnogram (after induction of anesthesia) were applied and basal readings were recorded.
- Preoxygenation with 100% oxygen for 3 minutes before induction.
Group (D):
Started infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia.
Induction:
- Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg).
Maintenance:
- Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes.
- IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h. Group (N)
Induction:
- Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg).
Maintenance:
- Maintenance of anesthesia was done with isoflurane inhalation at 1-2 (MAC) and incremental doses of rocuronium 0.5 mg/kg every 45 minutes.
- IV infusion of nitroglycerin at a dose of 0.5-2 µg/kg/min. Both drugs (dexmedetomidine and nitroglycerin) were titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline.
Operations for both groups were carried out by the same surgical team. All the patients, surgeons, and the attending anesthetist who was assigned to record the patients' parameters were blinded to the infused drugs. The randomization envelopes, the syringe pumps, and their code labels were prepared by an anesthetist independent in the study.
Recovery period:
Patients were recovered with neostigmine (0.05-0.08 mg/kg) and atropine, the standard analgesia (paracetamol) was started at a dose of (15 mg/kg) then patients were transferred to the post anesthesia care unit (PACU) for observation.
Measurements:
- The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system:-
Fromme and Boezaart scoring system:
Grade Assessment 0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible Heart rate and MAP basal readings were recorded then at 15 minutes time interval intraoperative.
Emergence time defined as the interval between discontinuation of the anesthetics to response of eye opening to the verbal command.
Recovery time defined as the time from end of surgery (i.e., final wound covered) until the patient left for the hospital ward were recorded.
The postoperative sedation was assessed with Ramsay Sedation Score Observation for any side effects or complications such as nausea, vomiting, shivering, dry mouth, bradycardia, tachycardia, and hypotension.
The cost of both drugs was recorded.
Data collection:
- Patient characteristics: age, sex, BMI, and physical status of patients included in the study.
- MAP, heart rate and assessment score of surgical field intraoperative.
- Emergence and recovery time.
- Sedation score.
- Drug cost.
- Side effects or complications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group D | Active comparator | Drug: controlled hypotension using dexmedetomidinedexmedetomidine as controlled hypotensive drug |
| Group N | Active comparator | Drug: controlled hypotension hypotension using nitroglycerinNitroglycerin as controlled hypotensive drug |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Physical status: American Society of Anesthesiologists (ASA) I \& II.
- Body Mass Index (BMI): 18.5-30 kg/m2.
- Type of operation: elective bilateral FESS.
- Type of anesthesia: general anesthesia.
Key exclusion criteria (5 listed)
- Patients with known history of allergy to study drugs.
- Anticipated difficult intubation.
- Advanced hepatic, renal or cardiovascular diseases.
- Central nervous system disorder, metabolic disease, and electrolyte imbalance.
- Coagulopathies or taking drugs affecting coagulation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| controlled hypotension using dexmedetomidineStarted infusion of a loading dose of dexmedetomidine 1 μg /kg over 10 minutes before induction of anesthesia. Induction: Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1mg/kg). Maintenance: Maintenance of anesthesia was done with isoflurane inhalation at 1-2 minimum alveolar concentration (MAC) and incremental doses of rocuronium 0.5mg/kg every 45 minutes. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h. Dexmedetomidine was titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline. | Drug | Group D |
| controlled hypotension hypotension using nitroglycerinInduction: • Fentanyl IV (2 μg/kg), Propofol IV (2 mg/kg), and Rocuronium IV (1 mg/kg). Maintenance: * Maintenance of anesthesia was done with isoflurane inhalation at 1-2 (MAC) and incremental doses of rocuronium 0.5 mg/kg every 45 minutes. * IV infusion of nitroglycerin at a dose of 0.5-2 µg/kg/min. Nitorglycerin) was titrated till mean arterial pressure (MAP) 60-70 mmHg, or a MAP below 30% of baseline. | Drug | Group N |
Primary outcome
The quality of the surgical field
Time frame: perioperative
The visibility of the surgical field was assessed by surgeon using Fromme and Boezaart scoring system: 0 No bleeding (cadaveric conditions) I Slight bleeding, no suctioning required II Slight bleeding, occasional suctioning required III Slight bleeding, frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed IV Moderate bleeding, frequent suctioning required, and bleeding threatens surgical field directly after suction is removed V Severe bleeding, constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible
Drug cost
Time frame: perioperative
estimate and compare the drug cost in both groups by Egyptian pounds
5 secondary outcomes
Emergence time
Time frame: perioperative
Mean arterial pressure
Time frame: basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes, 120 minutes
Heart rate
Time frame: basal, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 75 minutes, 90 minutes, 105 minutes , 120 minutes
Recovery time
Time frame: perioperative
Complications
Time frame: perioperative
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
- Individual participant dataSharing planned: No
Related trials for Intraoperative Bleeding
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
Active, not recruiting
Comparison of Intraoperative Outcomes of Microdebrider-Assisted Versus Conventional Functional Endoscopic Sinus Surgery in Patients With Sinonasal Polyposis
Nasal Polyps
Enrolling by invitation
Early Outcome of Simultaneous Bilateral Total Knee Replacement With and Without Tourniquet
Arthroplasty, Replacement, Knee, Blood Loss, Surgical
Recruiting
Hemocoll, Avitene, or Bone Wax for Cancellous Bone Bleeding After Single-Ray Amputation
Hemostasis, Surgical Blood Loss
Active, not recruitingObservational study
Safe and Timely Antithrombotic Removal (STAR) Registry
Hemorrhage, Surgical, Hemorrhage Postoperative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study of Intraoperative Bleeding and Functional Endoscopic Sinus Surgeries, run by Zagazig University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The quality of the surgical field (time frame: perioperative). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.